Publications: Prof Peter Szlosarek

Gallo B, Hussain R, Al-Jamal R, Khalid H, Stoker I, Hay G, Arora AK, Szlosarek PW et al. ( 2024 ) . Local tumour control and patient survival after ruthenium-106 brachytherapy for small choroidal melanoma . British Journal of Ophthalmology

Dulloo S, Lord S, Fennell DA, Thistlethwaite F, Maskell N, Popat S, Blyth KG, Szlosarek PW et al. ( 2024 ) . Phase 2 study to evaluate the novel mitochondrial PRX3 inhibitor, RSO-021, as an intrapleural monotherapy and in combination with IV paclitaxel in patients with malignant pleural effusion due to mesothelioma or another advanced solid tumor . Journal of Clinical Oncology vol. 42 , ( 16_suppl ) tps8124 - tps8124 .

Szlosarek PW, Creelan BC, Sarkodie T, Nolan L, Taylor P, Olevsky O, Grosso F, Cortinovis D et al. ( 2024 ) . Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma . JAMA Oncology vol. 10 , ( 4 ) 475 - 483 .

Pavlyk I, Carpentier J, Szlosarek EA, Chan PY, Bomalaski JS, Szlosarek PW ( 2024 ) . Abstract 4546: Pegargiminase and melphalan as a novel drug combination strategy for uveal melanoma . Cancer Research vol. 84 , ( 6_Supplement ) 4546 - 4546 .

Szlosarek PW, Dalgleish AG ( 2023 ) . Anti-cancer mechanisms involving the immune system . The Psychoimmunology of Cancer , Oxford University Press (OUP)

Szlosarek PW, Balkwill FR ( 2023 ) . Cytokines and cancer . Introduction to the Cellular and Molecular Biology of Cancer , Oxford University Press (OUP)

Griffiths GO, Griffiths D, Eminton Z, Hill K, Poile C, Nye M, Cave J, Danson S et al. ( 2023 ) . A randomised phase II trial of niraparib versus active symptom control in patients with previously treated mesothelioma: NERO . Journal of Clinical Oncology vol. 41 , ( 16_suppl ) tps8600 - tps8600 .

Phillips MM, Pavlyk I, Allen M, Ghazaly E, Cutts R, Carpentier J, Berry JS, Nattress C et al. ( 2023 ) . Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma . Pharmacological Reports vol. 75 , ( 3 ) 753 - 753 .

Szlosarek PW, Creelan B, Sarkodie T, Nolan L, Taylor P, Olevsky O, Grosso F, Cortinovis D et al. ( 2023 ) . Abstract CT007: Phase 2-3 trial of pegargiminase plus chemotherapy versus placebo plus chemotherapy in patients with non-epithelioid pleural mesothelioma . Cancer Research vol. 83 , ( 8_Supplement ) ct007 - ct007 .

Phillips MM, Pavlyk I, Allen M, Ghazaly E, Cutts R, Carpentier J, Berry JS, Nattress C et al. ( 2023 ) . A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma . Pharmacological Reports vol. 75 , ( 3 ) 570 - 584 .

Field GC, Pavlyk I, Szlosarek PW ( 2023 ) . Bench-to-Bedside Studies of Arginine Deprivation in Cancer . Molecules vol. 28 , ( 5 )

Barnett SE, Kenyani J, Tripari M, Butt Z, Grosman R, Querques F, Shaw L, Silva LC et al. ( 2023 ) . BAP1 loss is associated with higher ASS1 expression in epithelioid mesothelioma: implications for therapeutic stratification . Molecular Cancer Research vol. 21 , ( 5 ) 411 - 427 .

Carpentier J, Szlosarek P, Martin SA ( 2022 ) . 179 (PB059) The combination of the metabolism-based targeted therapies ADI-PEG20 and GC7 are a promising strategy for the treatment of malignant pleural mesothelioma . European Journal of Cancer vol. 174 ,

Dulloo S, Fennell DA, Szlosarek PW, Thistlethwaite F, Lord S, Rahman NM, Greystoke A, Cunniff B et al. ( 2022 ) . 1643TiP First-in-human dose-escalation and expansion study (MITOPE) to evaluate mitochondrial PRX3 inhibition by RSO-021 in patients with mesothelioma and other advanced solid tumors . Annals of Oncology vol. 33 , s1292 - s1293 .

Carpentier J, Pavlyk I, Mukherjee U, Hall PE, Szlosarek PW ( 2022 ) . Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy . Lung Cancer Targets and Therapy vol. 13 , 53 - 66 .

Szyszko TA, Dunn JT, Phillips MM, Bomalaski J, Sheaff MT, Ellis S, Pike L, Goh V et al. ( 2022 ) . Role of 3'-Deoxy-3'-[18F] Fluorothymidine Positron Emission Tomography-Computed Tomography as a Predictive Biomarker in Argininosuccinate Synthetase 1-Deficient Thoracic Cancers Treated With Pegargiminase . JTO Clinical and Research Reports vol. 3 , ( 9 )

Chan PY, Phillips MM, Ellis S, Johnston A, Feng X, Arora A, Hay G, Cohen VML et al. ( 2022 ) . A Phase 1 study of ADI‐PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1‐negative metastatic uveal melanoma . Pigment Cell & Melanoma Research vol. 35 , ( 4 ) 461 - 470 .

Zauderer MG, Szlosarek PW, Le Moulec S, Popat S, Taylor P, Planchard D, Scherpereel A, Koczywas M et al. ( 2022 ) . EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study . The Lancet Oncology vol. 23 , ( 6 ) 758 - 767 .

O'Day R, Grantham M, Thaung C, Szlosarek P, Sagoo MS ( 2022 ) . Tetrasomy of chromosomes 3 and 8 in a young male with choroidal melanoma . Melanoma Research vol. 32 , ( 2 ) 132 - 133 .

Chamberlain F, Lapuente M, Kirby P, Adebamowo A, Lau K, Ricketts W, Conibear J, Steele J et al. ( 2022 ) . 89 Service evaluation of diversity recruitment in thoracic cancer clinical trials at a tertiary cancer centre . Lung Cancer vol. 165 ,

Kefas J, Harwood C, Lewis MJ, Szlosarek P ( 2022 ) . Small vessel vasculitis and dry gangrene secondary to combined CTLA-4 and PD-1 blockade in malignant mesothelioma . BMC Rheumatology vol. 6 , ( 1 )

Fennell DA, Griffiths G, Ottensmeier C, Hanna GG, Danson S, Szlosarek P, Nye M ( 2022 ) . CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? – Authors' reply . The Lancet Oncology vol. 23 , ( 1 ) e14 - e15 .

Austin MJ, Halim L, Miraki-Moud F, Taussig D, Bomalaski J, Maher J, Gribben J, Szlosarek P et al. ( 2021 ) . Priming Death Receptor Mediated Apoptosis with Arginine Starvation Sensitises Arginine Auxotrophic B-ALL to CAR-T . Blood vol. 138 , ( Supplement 1 )

Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, Danson S, Steele N et al. ( 2021 ) . Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial . The Lancet Oncology vol. 22 , ( 11 ) 1530 - 1540 .

Szlosarek PW, Wimalasingham AG, Phillips MM, Hall PE, Chan PY, Conibear J, Lim L, Rashid S et al. ( 2021 ) . Phase 1, pharmacogenomic, dose‐expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1‐deficient non‐squamous non‐small cell lung cancer . Cancer Medicine vol. 10 , ( 19 ) 6642 - 6652 .

Chang K-Y, Chiang N-J, Wu S-Y, Yen C-J, Chen S-H, Yeh Y-M, Li C-F, Feng X et al. ( 2021 ) . Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers . OncoImmunology vol. 10 , ( 1 )

Fennell D, Ottensmeier C, Califano R, Hanna G, Ewings S, Hill K, Wilding S, Danson S et al. ( 2021 ) . PS01.11 Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial . Journal of Thoracic Oncology vol. 16 , ( 3 )

Fennell D, Ottensmeier C, Califano R, Hanna G, Ewings S, Hill K, Wilding S, Danson S et al. ( 2021 ) . Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial . JOURNAL OF THORACIC ONCOLOGY . vol. 16 , S62 - S62 .

Szlosarek PW, Phillips MM, Pavlyk I, Steele J, Shamash J, Spicer J, Kumar S, Pacey S et al. ( 2020 ) . Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed And Cisplatin in Patients With ASS1-Deficient Mesothelioma: Safety, Efficacy and Resistance Mechanisms . JTO Clinical and Research Reports100093 - 100093 .

Pavlyk I, Foster J, Dexter K, Sobasowski J, Bomalarski J, Berlato C, Balkwill F, Szlosarek PW ( 2020 ) . Abstract 2217: Pegylated arginine deiminase sensitizes ASS1-negative and KRAS mutant non-small cell lung cancer to PD-1 blockade immunotherapy . Cancer Research . vol. 80 , 2217 - 2217 .

Hall PE, Ready N, Johnston A, Bomalaski JS, Venhaus RR, Sheaff M, Krug L, Szlosarek PW ( 2020 ) . Phase II Study of Arginine Deprivation Therapy With Pegargiminase in Patients With Relapsed Sensitive or Refractory Small-cell Lung Cancer . Clinical Lung Cancer vol. 21 , ( 6 ) 527 - 533 .

Wong P-P, Muñoz-Félix JM, Hijazi M, Kim H, Robinson SD, De Luxán-Delgado B, Rodríguez-Hernández I, Maiques O et al. ( 2020 ) . Cancer Burden Is Controlled by Mural Cell-β3-Integrin Regulated Crosstalk with Tumor Cells . Cell vol. 181 , ( 6 ) 1346 - 1363.e21 .

Zauderer MG, Szlosarek PW, Le Moulec S, Popat S, Taylor P, Planchard D, Scherpereel A, Jahan TM et al. ( 2020 ) . Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) 9058 - 9058 .

Szlosarek P ( 2019 ) . ES03.04 Pegargiminase to Treat Mesothelioma . Journal of Thoracic Oncology . vol. 14 , s19 - s20 .

Tsao M-S, Carbone M, Galateau-Salle F, Moreira AL, Nicholson AG, Roden AC, Adjei AA, Aubry M-C et al. ( 2019 ) . Pathologic Considerations and Standardization in Mesothelioma Clinical Trials . Journal of Thoracic Oncology vol. 14 , ( 10 ) 1704 - 1717 .

Wimalasingham AG, Phillips MM, Lim L, Rashid S, Hall PE, Khadeir R, Steele JPC, Conibear J et al. ( 2019 ) . Phase 1 dose-expansion study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with argininosuccinate synthetase 1 (ASS1)–deficient non-squamous non-small cell lung cancer . Journal of Clinical Oncology vol. 37 , ( 15_suppl ) 9097 - 9097 .

Hall PE, Lewis R, Syed N, Shaffer R, Evanson J, Ellis S, Williams M, Feng X et al. ( 2019 ) . A phase I study of pegylated arginine deiminase (Pegargiminase), cisplatin, and pemetrexed in argininosuccinate synthetase 1-deficient recurrent high-grade glioma . Clinical Cancer Research vol. 25 , ( 9 ) 2708 - 2716 .

Turner EC, Szlosarek PW, Vousden KH ( 2019 ) . Argininosuccinate Synthetase (ASS1) Expression in Pancreatic Ductal Adenocarcinoma and Response to Arginine Deprivation . JOURNAL OF PATHOLOGY . vol. 248 , S21 - S21 .

Kawsar A, Patel P, Markiewicz D, Szlosarek P, Phillips M, Harwood C ( 2019 ) . Histological features of cutaneous toxicity with checkpoint-inhibitor immunotherapy for metastatic melanoma: a retrospective case series . BRITISH JOURNAL OF DERMATOLOGY . vol. 181 , 117 - 117 .

Przystal JM, Hajji N, Khozoie C, Renziehausen A, Zeng Q, Abaitua F, Hajitou A, Suwan K et al. ( 2018 ) . Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM . Cell Death & Disease vol. 9 , ( 12 )

Renziehausen A, Wang H, Rao B, Weir L, Nigro CL, Lattanzio L, Merlano M, Vega-Rioja A et al. ( 2019 ) . The renin angiotensin system (RAS) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention . Oncogene . vol. 38 , 2320 - 2336 .

Atkinson A, Renziehausen A, Wang H, Lo Nigro C, Lattanzio L, Merlano M, Rao B, Weir L et al. ( 2018 ) . Collagen Prolyl Hydroxylases Are Bifunctional Growth Regulators in Melanoma . Journal of Investigative Dermatology vol. 139 , ( 5 ) 1118 - 1126 .

Hall P, Lewis R, Syed N, Shaffer R, Evanson J, Ellis S, Williams M, Feng X et al. ( 2018 ) . A PHASE I EXPANSION STUDY OF PEGARGIMINASE, CISPLATIN AND PEMETREXED IN ARGININOSUCCINATE SYNTHETASE 1-NEGATIVE RECURRENT HIGH GRADE GLIOMAS (HGGS) . Neuro-Oncology . vol. 20 , v345 - v345 .

Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM et al. ( 2018 ) . Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation . Journal of Thoracic Oncology vol. 13 , ( 11 ) 1655 - 1667 .

Keshet R, Szlosarek P, Carracedo A, Erez A ( 2018 ) . Rewiring urea cycle metabolism in cancer to support anabolism . Nature Reviews Cancer vol. 18 , ( 10 ) 634 - 645 .

Phillips M, Szyszko T, Hall P, Rashid S, Khadeir R, Lim L, Steele J, Conibear J et al. ( 2018 ) . Abstract B33: Expansion study of pegylated arginine deiminase (ADI-PEG20), pemetrexed, and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer (TRAP) . Clinical Cancer Research . vol. 24 , b33 - b33 .

Crusz SM, Radunovic A, Shepherd S, Shah S, Newey V, Phillips M, Lim L, Powles T et al. ( 2018 ) . Rituximab in the treatment of pembrolizumab-induced myasthenia gravis . European Journal of Cancer vol. 102 , 49 - 51 .

Hall PE, Lewis R, Syed N, Shaffer R, Evanson J, Ellis S, Williams M, Feng X et al. ( 2018 ) . A phase I expansion study of pegargiminase, cisplatin, and pemetrexed in argininosuccinate synthetase 1-negative recurrent high grade gliomas (HGGs) . Journal of Clinical Oncology vol. 36 , ( 15_suppl ) e14085 - e14085 .

Fennell DA, Kirkpatrick EV, Cozens K, Danson S, Hanna GG, Lester JF, Lord J, Nye M et al. ( 2018 ) . CONFIRM: A phase III randomized trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma . Journal of Clinical Oncology . vol. 36 , tps8586 - tps8586 .

Chan PY, Phillips MM, Khadeir R, Ellis S, Thomson J, Johnston A, Feng X, Wu B-W et al. ( 2018 ) . Phase 1 study of pegargiminase combined with cisplatin and pemetrexed in patients with ASS1-deficient uveal melanoma . Journal of Clinical Oncology . vol. 36 , 2589 - 2589 .

Zauderer MG, Szlosarek P, Le Moulec S, Popat S, Taylor P, Planchard D, Scherpereel A, Jahan T et al. ( 2018 ) . Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation . Journal of Clinical Oncology . vol. 36 , 8515 - 8515 .

Fennell DA, Kirkpatrick E, Cozens K, Nye M, Lester J, Hanna G, Steele N, Szlosarek P et al. ( 2018 ) . CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial . Trials vol. 19 , ( 1 )

Hanna G, Griffiths G, Kirkpatrick EV, Cozens K, Kalevras M, Maishman T, Danson S, Lester J et al. ( 2018 ) . 190 CONFIRM: a phase III randomised trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma . Lung Cancer vol. 115 ,

Hanna G, Griffiths G, Kirkpatrick EV, Cozens K, Kalevras M, Maishman T, Danson S, Lester J et al. ( 2018 ) . CONFIRM: a phase III randomised trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma . LUNG CANCER . vol. 115 , S84 - S84 .

Cohen VML, Pavlidou E, DaCosta J, Arora AK, Szyszko T, Sagoo MS, Szlosarek P ( 2018 ) . Staging Uveal Melanoma with Whole-Body Positron-Emission Tomography/Computed Tomography and Abdominal Ultrasound: Low Incidence of Metastatic Disease, High Incidence of Second Primary Cancers . Middle East African Journal of Ophthalmology vol. 25 , ( 2 ) 91 - 95 .

Fennell D, Kirkpatrick E, Cozens K, Danson S, Hanna G, Lester J, Lord J, Nye M et al. ( 2017 ) . PUB035 CONFIRM: A Phase III Randomized Trial to Evaluate the Efficacy of Nivolumab versus Placebo in Relapsed Mesothelioma . Journal of Thoracic Oncology . vol. 12 ,

Khadeir R, Szyszko T, Szlosarek PW ( 2017 ) . Optimizing arginine deprivation for hard-to-treat cancers . Oncotarget vol. 8 , ( 57 ) 96468 - 96469 .

Chan PY, Hall P, Hay G, Cohen VML, Szlosarek PW ( 2017 ) . A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity . Pigment Cell Melanoma Res vol. 30 , ( 6 ) 558 - 562 .

Szlosarek PW, Baas P, Ceresoli GL, Fennell DA, Gilligan D, Johnston A, Lee P, Mansfield AS et al. ( 2017 ) . ATOMIC-Meso: A randomized phase 2/3 trial of ADI-PEG20 or placebo with pemetrexed and cisplatin in patients with argininosuccinate synthetase 1-deficient non-epithelioid mesothelioma . Journal of Clinical Oncology . vol. 35 , tps8582 - tps8582 .

Phillips M, Szyszko T, Hall P, Cook GJR, Khadeir R, Steele JPC, Spicer JF, Feng X et al. ( 2017 ) . Expansion study of ADI-PEG 20, pemetrexed and cisplatin in patients with ASS1-deficient malignant pleural mesothelioma (TRAP) . Journal of Clinical Oncology . vol. 35 , 8553 - 8553 .

Beddowes E, Spicer J, Chan PY, Khadeir R, Corbacho JG, Repana D, Steele JP, Schmid P et al. ( 2017 ) . Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers . Journal of Clinical Oncology vol. 35 , ( 16 )

Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S et al. ( 2017 ) . Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial . JAMA Oncology vol. 3 , ( 1 ) 58 - 66 .

Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S et al. ( 2017 ) . Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma a randomized clinical trial . JAMA Oncology vol. 3 , ( 1 ) E1 - E9 .

Adams E, Cheng C-Y, Sacco J, Danson S, Corrie P, Nathan P, Szlosarek P, Upton J et al. ( 2017 ) . Mapping the treatment pathway for metastatic uveal melanoma (mUM) patients in England: <i>A qualitative pilot study</i> . JOURNAL FOR IMMUNOTHERAPY OF CANCER . vol. 5 ,

Locke M, Ghazaly E, Freitas MO, Mitsinga M, Lattanzio L, Lo Nigro C, Nagano A, Wang J et al. ( 2016 ) . Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1 . Cell Reports vol. 16 , ( 6 ) 1604 - 1613 .

Szlosarek PW, Locke M, Ghazaly E, Lattanzio L, Lo Nigro C, Martin SA ( 2016 ) . Abstract 1050: Inhibition of the polyamine synthesis pathway is synthetically lethal with loss of argininosuccinate synthase 1 in cancer . vol. 76 , is. 14_Supplement , pp. 1050 - 1050 . American Association for Cancer Research (AACR)

Szlosarek PW, Szyszko T, Pacey S, Spicer JF, Phillips M, Steele JPC, Barba A, Diaz M et al. ( 2016 ) . 18-FLT-PET/CT as an imaging biomarker in patients with ASS1-deficient thoracic cancers treated with ADI-PEG20, pemetrexed and cisplatin . Journal of Clinical Oncology . vol. 34 , 11567 - 11567 .

Burrows N, Cane G, Robson M, Gaude E, J. Howat W, Szlosarek PW, Pedley RB, Frezza C et al. ( 2016 ) . Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI-PEG20) . Scientific Reports vol. 6 , ( 1 )

( 2016 ) . Erratum . Autophagy vol. 12 , ( 2 ) 443 - 443 .

Karydis I, Chan PY, Wheater M, Arriola E, Szlosarek PW, Ottensmeier CH ( 2016 ) . Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma . OncoImmunology vol. 5 , ( 5 )

Allen M, Syed N, Crook T, Jones L, Lemoine NR, Berney D, Szlosarek P ( 2010 ) . Abstract A23: Frequent ASS1 deficiency in bladder cancer and sensitivity to pegylated arginine deiminase (ADI-PEG20): A potential novel therapeutic strategy . Clinical Cancer Research . vol. 16 , a23 - a23 .

Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM et al. ( 2016 ) . Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) . Autophagy vol. 12 , ( 1 ) 1 - 222 .

Szyszko TA, Yip C, Szlosarek P, Goh V, Cook GJ ( 2016 ) . The role of new PET tracers for lung cancer . Lung cancer (Amsterdam, Netherlands) vol. 94 , 7 - 14 .

Szyszko TA, Bomalaski JS, Goh V, Barrington SF, Cook GJR, Szlosarek PW ( 2016 ) . TRAP substudy: assessment of 18-FLT PET/CT to examine tumour proliferation in patients with ASS1-deficient thoracic cancers treated with arginine deiminase (ADI)-PEG20, pemetrexed and cisplatin . EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING . vol. 43 , S354 - S354 .

Pacey S, Spicer JF, Chan PY, Hategan M, Repana D, Steele JP, Schmid P, Cook GJR et al. ( 2015 ) . Abstract B23: A phase 1 study in patients with mesothelioma or non small cell lung tumours requiring arginine to assess ADI-PEG 20 with pemetrexed and cisplatin (TRAP study) . Molecular Cancer Therapeutics . vol. 14 , b23 - b23 .

Rintoul RC, Rassl DM, Gittins J, Marciniak SJ, Black F, Blyth KG, Booton R, Cane P et al. ( 2015 ) . MesobanK UK: an international mesothelioma bioresource . Thorax vol. 71 , ( 4 )

Nathan P, Cohen V, Coupland S, Curtis K, Damato B, Evans J, Fenwick S, Kirkpatrick L et al. ( 2015 ) . Uveal Melanoma UK National Guidelines . European Journal of Cancer vol. 51 , ( 16 ) 2404 - 2412 .

Khadeir RS, Phillips MM, Sgoo MS, Arora A, Cohen V, Thaung C, Szlosarek PW ( 2015 ) . Abstract 1156: Widespread deficiency of ASS1 in uveal melanoma and sensitivity to pegylated arginine deiminase . Cancer Research . vol. 75 , 1156 - 1156 .

Pazmandi J, O'Neill KS, Scheck AC, Szlosarek PW, Woolf EC, Brooks KS, Syed N ( 2015 ) . Abstract 240: The ketogenic diet alters the expression of microRNAs that play key roles in tumor development . Cancer Research . vol. 75 , 240 - 240 .

Phillips MM, Khadeir R, Tookman L, McCarthy F, Steele J, Bomalaski J, Ghazaly E, Szlosarek PW ( 2015 ) . Abstract 3360: Macrophages promote resistance to pegylated arginine deiminase in malignant pleural mesothelioma . Cancer Research . vol. 75 , 3360 - 3360 .

Szlosarek PW, Spicer JF, Szyszko T, Cook GJR, Chan PY, Hategan M, Repana D, Steele JP et al. ( 2015 ) . Phase I study of ADI-PEG 20 in combination with pemetrexed and cisplatin (TRAP) in patients with ASS1-deficient mesothelioma and non-squamous lung cancer . Journal of Clinical Oncology . vol. 33 , tps2612 - tps2612 .

Miraki-Moud F, Ghazaly E, Ariza-McNaughton L, Hodby KA, Clear A, Anjos-Afonso F, Liapis K, Grantham M et al. ( 2015 ) . Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo . Blood vol. 125 , ( 26 ) 4060 - 4068 .

Gale J, Van-de-Velde V, Szlosarek P, Langhurst H, Harwood C ( 2015 ) . Two diverse skin complications of common variable immunodeficiency . BRITISH JOURNAL OF DERMATOLOGY . vol. 173 , 139 - 140 .

Szlosarek PW, Lee S, Pollard PJ ( 2014 ) . Rewiring Mitochondrial Pyruvate Metabolism: Switching Off the Light in Cancer Cells? . Molecular Cell vol. 56 , ( 3 ) 343 - 344 .

Cutts R, Jithesh PV, Delage B, Luong P, Thomas G, Chelala C, Szlosarek PW ( 2014 ) . Abstract 1431: Gene expression analysis of argininosuccinate synthetase loss and the effects of pegylated arginine deiminase in malignant pleural mesothelioma . Cancer Research . vol. 74 , 1431 - 1431 .

Szlosarek PW ( 2014 ) . Arginine deprivation and autophagic cell death in cancer . Proc Natl Acad Sci U S A vol. 111 , ( 39 ) 14015 - 14016 .

Ghazaly EA, Luong P, Chmielewska-Kassassir M, Wozniak L, Bomalaski JS, Gribben JG, Szlosarek PW ( 2014 ) . Metabolomic analysis of pegylated arginine deiminase treatment in patients with malignant pleural mesothelioma . Journal of Clinical Oncology . vol. 32 , 7587 - 7587 .

Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer JF, Lind MJ, Bomalaski JS et al. ( 2014 ) . Randomized trial of arginine deprivation with pegylated arginine deiminase in patients with malignant pleural mesothelioma . Journal of Clinical Oncology . vol. 32 , 7507 - 7507 .

Rintoul RC, Rassl DM, Maskell N, Gittins J, Szlosarek PW, Kerr KM, Booton R, Hughes V et al. ( 2014 ) . MesobanK - a UK based bioresource for malignant mesothelioma . LUNG CANCER vol. 83 , S82 - S82 .

Pavlidou E, Arora A, Somerville E, Sagoo MS, Szlosarek P, Cohen V ( 2014 ) . The value of whole body (18) fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) and abdominal ultrasound in staging of patients with uveal melanoma . INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE . vol. 55 ,

Phillips MM, Sheaff MT, Szlosarek PW ( 2013 ) . Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges . Cancer Res Treat vol. 45 , ( 4 ) 251 - 262 .

Allen MD, Luong P, Hudson C, Leyton J, Delage B, Ghazaly E, Cutts R, Yuan M et al. ( 2013 ) . Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging . Cancer Research vol. 74 , ( 3 ) 896 - 907 .

Miraki-Moud F, Ariza-McNaughton L, Ghazaly EA, Hodby KA, Luong P, Clear A, Sohrabi F, Bomalaski J et al. ( 2013 ) . Arginine Deprivation With Pegylated Arginine Deiminase Induces Death Of Acute Myeloid Leukaemia Cells In Vivo . Blood . vol. 122 ,

Ghazaly EA, Luong P, Chmielewska-Kassasir M, Hudson C, Bomalaski JS, Wozniak L, Avril NE, Joel SP et al. ( 2013 ) . Abstract 1885: A comprehensive untargeted UPLC-MS based metabolomic analysis of ASS1 -deficient solid tumor cell lines treated with arginine deiminase . Cancer Research . vol. 73 , 1885 - 1885 .

Zheng L, MacKenzie ED, Karim SA, Hedley A, Blyth K, Kalna G, Watson DG, Szlosarek P et al. ( 2013 ) . Reversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells . Cancer Metab vol. 1 , ( 1 )

Szlosarek PW, Luong P, Phillips MM, Baccarini M, Stephen E, Szyszko T, Sheaff MT, Avril N ( 2013 ) . Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase . J Clin Oncol vol. 31 , ( 7 ) e111 - e113 .

Syed N, Langer J, Janczar K, Singh P, Lo Nigro C, Lattanzio L, Coley HM, Hatzimichael E et al. ( 2013 ) . Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma . Cell Death Dis vol. 4 , ( 1 )

Szlosarek PW, Steele J, Sheaff M, Szyszko T, Ellis S, Nolan L, Taylor P, Gilligan D et al. ( 2013 ) . A RANDOMISED PHASE II TRIAL OF PEGYLATED ARGININE DEIMINASE IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA . JOURNAL OF THORACIC ONCOLOGY vol. 8 , S308 - S308 .

Rintoul RC, Rassl DM, Maskell NA, Szlosarek PW, Kerr KM, Booton R, Hughes V, Fennell D et al. ( 2013 ) . MESOBANK: A UK BASED BIORESOURCE FOR MALIGNANT PLEURAL MESOTHELIOMA . JOURNAL OF THORACIC ONCOLOGY . vol. 8 , S940 - S940 .

Matin RN, Szlosarek P, McGregor JM, Cerio R, Harwood CA ( 2013 ) . Synchronous melanoma and renal carcinoma: a clinicopathological study of five cases . Clin Exp Dermatol vol. 38 , ( 1 ) 47 - 49 .

Lewis A, Hough N, Woolf DK, Trehy R, Kolotia B, Reeves A, Szlosarek PW, Wells P et al. ( 2013 ) . Systemic therapy in the management of non small cell lung cancer (NSCLC): The real world experience . LUNG CANCER vol. 79 , S17 - S17 .

Hough N, Lewis A, Woolf DK, Trehy R, Kolotia B, Reeves A, Szlosarek PW, Wells P et al. ( 2013 ) . Three years experience of chemotherapy for small cell lung cancer at a tertiary referral centre . LUNG CANCER vol. 79 , S65 - S65 .

Sommerlad M, Purdie K, Rizvi H, McGregor JM, Szlosarek P, Wolstenholme V, Cerio R, Harwood C ( 2013 ) . Vemurafenib, photosensitivity and human papillomavirus infection: an emerging story . BRITISH JOURNAL OF DERMATOLOGY . vol. 169 , 9 - 9 .

Coward JIG, Ding N-L, Feakins R, Kocher H, Popat S, Szlosarek PW ( 2012 ) . Chemotherapy-induced bowel obstruction in small cell lung cancer: a case report . Med Oncol vol. 29 , ( 4 ) 2623 - 2625 .

Szlosarek PW, Dalgleish AG ( 2012 ) . Potential Applications of Gene Therapy in the Patient with Cancer . Drugs & Aging vol. 17 , ( 2 ) 121 - 132 .

Delage B, Luong P, Maharaj L, O'Riain C, Syed N, Crook T, Hatzimichael E, Papoudou-Bai A et al. ( 2012 ) . Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis . Cell Death Dis vol. 3 , ( 7 )

Hatzimichael E, Dasoula A, Syed N, Szlosarek PW, Dranitsaris G, Crook T, Briasoulis EC ( 2012 ) . Epigenetic inactivation to target the arginine biosynthetic pathway in multiple myeloma . Journal of Clinical Oncology vol. 30 , ( 15_suppl ) e18567 - e18567 .

Wang H, Lee S, Nigro CL, Lattanzio L, Merlano M, Monteverde M, Matin R, Purdie K et al. ( 2012 ) . NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity . Br J Cancer vol. 106 , ( 8 ) 1446 - 1452 .

Matin RN, Gonzalez D, Thompson L, Lambert SR, Bakr F, Dhomen N, Marais R, McGregor JM et al. ( 2012 ) . KIT and BRAF mutational status in a patient with a synchronous lentigo maligna melanoma and a gastrointestinal stromal tumor . Am J Clin Dermatol vol. 13 , ( 1 ) 64 - 65 .

Hatzimichael E, Dasoula A, Syed N, Szlosarek PW, Dranitsaris G, Crook T, Briasoulis EC ( 2012 ) . Epigenetic inactivation to target the arginine biosynthetic pathway in multiple myeloma . JOURNAL OF CLINICAL ONCOLOGY . vol. 30 ,

Syed N, Roncaroli F, Janczar K, Singh P, O'Neil K, Lo Nigro C, Lattanzio L, Coley HM et al. ( 2012 ) . TRANSCRIPTIONAL SILENCING DISRUPTS TWO LEVELS OF ARGININE BIOSYNTHESIS IN GLIOBLASTOMA MULTIFORME (GBM): A NOVEL, TARGETED THERAPEUTIC STRATEGY FOR GBM . NEURO-ONCOLOGY . vol. 14 , 11 - 11 .

Hatzimichael E, Dasoula A, Syed N, Szlosarek P, Dranitsaris G, Crook T, Briasoulis E ( 2011 ) . Epigenetic Inactivation Targets the Arginine Biosynthetic Pathway At Two Levels in Multiple Myeloma . Blood vol. 118 , ( 21 )

Delage B, Luong P, Phillips M, Chmielewska-Kassassir M, Cutts R, Chelala C, Ghazaly E, Jithesh PV et al. ( 2011 ) . Abstract B139: Arginine deprivation with pegylated arginine deiminase regulates key metabolic genes in RNA and DNA synthesis in ASS1-deficient malignant mesothelioma cells: Clinical implications . Molecular Cancer Therapeutics . vol. 10 , b139 - b139 .

Phillips M, Szlosarek PW ( 2011 ) . Arginine Metabolism and Tumour-Associated Macrophages . Tumour-Associated Macrophages , Springer Nature

Syed N, Coley HM, Sehouli J, Koensgen D, Mustea A, Szlosarek P, McNeish I, Blagden SP et al. ( 2011 ) . Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer . Cancer Res vol. 71 , ( 9 ) 3317 - 3327 .

Szlosarek PW, Luong F, Clear A, Taussig D, Joel S, Calaminici M, Debernardi S, Fitzgibbon J et al. ( 2011 ) . Abstract 4067: Pegylated arginine deiminase (ADI-PEG20) as a potential novel therapy for argininosuccinate synthetase-deficient acute myeloid leukemia . Cancer Research . vol. 71 , 4067 - 4067 .

Allen M, Syed N, Luong F, Howarth K, Gorman P, Tomlinson I, Roylance R, Lu Y-J et al. ( 2011 ) . Abstract 76: Epigenetic silencing of argininosuccinate synthetase renders human bladder cancer cells sensitive to pegylated arginine deiminase . Cancer Research vol. 71 , ( 8_Supplement ) 76 - 76 .

Syed N, O'Neill K, Hughes M, LoNigro C, Lattanzio L, Szlosarek P, Roncaroli F, Crook T ( 2011 ) . Abstract LB-260: Transcriptional silencing disrupts two levels of arginine biosynthesis in glioblastoma multiforme: a novel, targeted therapeutic strategy for high grade gliomas . Cancer Research vol. 71 , ( 8_Supplement )

Szlosarek PW, Luong F, Clear A, Taussig D, Joel S, Calaminici M, Debernardi S, Fitzgibbon J et al. ( 2011 ) . Pegylated arginine deiminase (ADI-PEG20) as a potential novel therapy for argininosuccinate synthetase-deficient acute myeloid leukemia . CANCER RESEARCH . vol. 71 ,

Delage B, Fennell DA, Nicholson L, McNeish I, Lemoine NR, Crook T, Szlosarek PW ( 2010 ) . Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer . Int J Cancer vol. 126 , ( 12 ) 2762 - 2772 .

Szlosarek PW, Delage B, O'Riain C, Hatzimichael E, Crook T, Calaminici M, Gribben JG, Lemoine N et al. ( 2010 ) . Effect of inactivation of argininosuccinate synthetase on sensitivity of lymphomas to caspase-dependent apoptosis following treatment with arginine deiminase . Journal of Clinical Oncology vol. 28 , ( 15_suppl ) 8093 - 8093 .

Delage B, Chelala C, Chacko A, Jithesh PV, Fennell DA, Lemoine NR, Szlosarek PW ( 2010 ) . Abstract 4445: Pegylated arginine deiminase induces mitochondrial apoptosis and synergizes with cisplatin in ASS1-negative malignant pleural mesothelioma . Cancer Research . vol. 70 , 4445 - 4445 .

Nicholson LJ, Smith PR, Hiller L, Szlosarek PW, Kimberley C, Sehouli J, Koensgen D, Mustea A et al. ( 2009 ) . Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer . Int J Cancer vol. 125 , ( 6 ) 1454 - 1463 .

Matin RN, Harwood CA, McAndrew L, Cerio R, Szlosarek P ( 2009 ) . A clinicopathological study of cases of synchronous melanoma and renal carcinoma . BRITISH JOURNAL OF DERMATOLOGY . vol. 161 , 19 - 19 .

Lim SL, Smith P, Syed N, Coens C, Wong H, van der Burg M, Szlosarek P, Crook T et al. ( 2008 ) . Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer . BRIT J CANCER vol. 98 , ( 8 ) 1452 - 1456 .

Szlosarek PW, Grimshaw MJ, Wilbanks GD, Hagemann T, Wilson JL, Burke F, Stamp G, Balkwill FR ( 2007 ) . Aberrant regulation of argininosuccinate synthetase by TNF-alpha in human epithelial ovarian cancer . Int J Cancer vol. 121 , ( 1 ) 6 - 11 .

Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, Grimshaw MJ, Steele JP et al. ( 2006 ) . In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion . Clin Cancer Res vol. 12 , ( 23 ) 7126 - 7131 .

Szlosarek PW, Fennell DA, Rudd RM, Lind M, Ranson M, Hackshaw A, Bomalaski JS, Steele JPC ( 2006 ) . A randomized phase II trial of pegylated arginine deaminase (ADI-PEG 20) in patients with malignant pleural mesothelioma . LUNG CANCER vol. 54 , S54 - S54 .

Szlosarek P, Charles KA, Balkwill FR ( 2006 ) . Tumour necrosis factor-alpha as a tumour promoter . Eur J Cancer vol. 42 , ( 6 ) 745 - 750 .

Szlosarek PW, Grimshaw MJ, Kulbe H, Wilson JL, Wilbanks GD, Burke F, Balkwill FR ( 2006 ) . Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium . Mol Cancer Ther vol. 5 , ( 2 ) 382 - 390 .

Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Balkwill FR, Fennell D ( 2006 ) . Arginine depletion upregulates Bax and triggers apoptosis of malignant mesothelioma cells deficient in argininosuccinate synthetase . CANCER RESEARCH . vol. 66 ,

Kulbe H, Hagemann T, Szlosarek PW, Balkwill FR, Wilson JL ( 2005 ) . The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells . Cancer Res vol. 65 , ( 22 ) 10355 - 10362 .

Szlosarek PW, Grimshaw MJ, Wilbanks GD, Burke F, Wilson JL, Balkwill FR ( 2004 ) . Regulation and expression of argininosuccinate synthetase in human ovarian cancer . BRITISH JOURNAL OF CANCER . vol. 91 , S57 - S57 .

Szlosarek P, Balkwill F ( 2004 ) . The inflammatory cytokine network of epithelial cancer: therapeutic implications . Novartis Found Symp vol. 256 , 227 - 237 .

Szlosarek PW, Balkwill FR ( 2003 ) . Tumour necrosis factor alpha: a potential target for the therapy of solid tumours . Lancet Oncol vol. 4 , ( 9 ) 565 - 573 .

Nicholson S, Guile K, John J, Clarke IA, Diffley J, Donnellan P, Michael A, Szlosarek P et al. ( 2003 ) . A randomized phase II trial of SRL172 (Mycobacterium vaccae) +/- low-dose interleukin-2 in the treatment of metastatic malignant melanoma . MELANOMA RES vol. 13 , ( 4 ) 389 - 393 .

Szlosarek PW ( 2001 ) . Recent advances in palliative care - United Kingdom continues to lead in palliative care . BRIT MED J vol. 322 , ( 7280 ) 234 - 234 .

Szlosarek PW, Lofts FJ, Pettengell R, Carter P, Young M, Harmer C ( 2000 ) . Effective treatment of a patient with a high-grade endometrial stromal sarcoma with an accelerated regimen of carboplatin and paclitaxel . Anti-Cancer Drugs vol. 11 , ( 4 ) 275 - 278 .